Literature DB >> 25782672

Intra-individual plasticity of the TAZ gene leading to different heritable mutations in siblings with Barth syndrome.

Lorenzo Ferri1,2, Maria A Donati3, Silvia Funghini2, Catia Cavicchi2, Viviana Pensato4, Cinzia Gellera4, Federica Natacci5, Luigina Spaccini6, Serena Gasperini7, Frédéric M Vaz8, David N Cooper9, Renzo Guerrini1,2, Amelia Morrone1,2.   

Abstract

Infantile-onset skeletal myopathy Barth syndrome (OMIM #302060) is caused by mutations in the X-linked TAZ gene and hence usually manifests itself only in hemizygous males. Confirmatory testing is provided by mutational analysis of the TAZ gene and/or by biochemical dosage of the monolysocardiolipin/tetralinoleoyl cardiolipin ratio. Heterozygous females do not usually display a clinical phenotype but may undergo molecular genetic prenatal diagnosis during pregnancy. We characterized two novel and non-identical TAZ gene rearrangements in the offspring of a single female carrier of Barth syndrome. The hg19chrX:g.153634427_153644361delinsKP_123427.1 TAZ gene rearrangement was identified in her affected son, whereas the NM_000116.3(TAZ)c.-72_109+51del TAZ gene deletion was identified in a male foetus during a subsequent pregnancy. The unaffected mother was surprisingly found to harbour both variants in addition to a wild-type TAZ allele. A combination of breakpoint junction sequencing, linkage analysis and assessment of allelic dosage revealed that the two variants had originated independently from an apparently unstable/mutable TAZ maternal allele albeit via different mutational mechanisms. We conclude that molecular prenatal diagnosis in Barth syndrome families with probands carrying TAZ gene rearrangements should include investigation of the entire coding region of the TAZ gene. The identification of the breakpoint junctions of such gross gene rearrangements is important to ensure accurate ascertainment of carriership with a view to providing appropriate genetic counselling.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25782672      PMCID: PMC4795190          DOI: 10.1038/ejhg.2015.50

Source DB:  PubMed          Journal:  Eur J Hum Genet        ISSN: 1018-4813            Impact factor:   4.246


  34 in total

1.  Fabry disease: molecular studies in Italian patients and X inactivation analysis in manifesting carriers.

Authors:  A Morrone; C Cavicchi; T Bardelli; D Antuzzi; R Parini; M Di Rocco; S Feriozzi; O Gabrielli; R Barone; G Pistone; C Spisni; R Ricci; E Zammarchi
Journal:  J Med Genet       Date:  2003-08       Impact factor: 6.318

2.  Monolysocardiolipins accumulate in Barth syndrome but do not lead to enhanced apoptosis.

Authors:  Fredoen Valianpour; Voula Mitsakos; Dimitri Schlemmer; Jeffrey A Towbin; Juliet M Taylor; Paul G Ekert; David R Thorburn; Arnold Munnich; Ronald J A Wanders; Peter G Barth; Frédéric M Vaz
Journal:  J Lipid Res       Date:  2005-04-01       Impact factor: 5.922

3.  X-linked dilated cardiomyopathy with neutropenia, growth retardation, and 3-methylglutaconic aciduria.

Authors:  R I Kelley; J P Cheatham; B J Clark; M A Nigro; B R Powell; G W Sherwood; J T Sladky; W P Swisher
Journal:  J Pediatr       Date:  1991-11       Impact factor: 4.406

4.  Cardiac and clinical phenotype in Barth syndrome.

Authors:  Carolyn T Spencer; Randall M Bryant; Jane Day; Iris L Gonzalez; Steven D Colan; W Reid Thompson; Julie Berthy; Sharon P Redfearn; Barry J Byrne
Journal:  Pediatrics       Date:  2006-07-17       Impact factor: 7.124

5.  Multiple mutation in an extended Duchenne muscular dystrophy family.

Authors:  A Miciak; A Keen; D Jadayel; S Bundey
Journal:  J Med Genet       Date:  1992-02       Impact factor: 6.318

6.  Cardiolipin and monolysocardiolipin analysis in fibroblasts, lymphocytes, and tissues using high-performance liquid chromatography-mass spectrometry as a diagnostic test for Barth syndrome.

Authors:  Riekelt H Houtkooper; Richard J Rodenburg; Charlotte Thiels; Henk van Lenthe; Femke Stet; Bwee Tien Poll-The; Janet E Stone; Colin G Steward; Ronald J Wanders; Jan Smeitink; Willem Kulik; Frédéric M Vaz
Journal:  Anal Biochem       Date:  2009-01-31       Impact factor: 3.365

7.  Deficiency of tetralinoleoyl-cardiolipin in Barth syndrome.

Authors:  Michael Schlame; Jeffrey A Towbin; Paul M Heerdt; Roswitha Jehle; Salvatore DiMauro; Thomas J J Blanck
Journal:  Ann Neurol       Date:  2002-05       Impact factor: 10.422

8.  Barth syndrome without tetralinoleoyl cardiolipin deficiency: a possible ameliorated phenotype.

Authors:  Ann Bowron; Julie Honeychurch; Maggie Williams; Beverley Tsai-Goodman; Nicol Clayton; Lucy Jones; Graham J Shortland; Shakeel A Qureshi; Simon J R Heales; Colin G Steward
Journal:  J Inherit Metab Dis       Date:  2014-08-12       Impact factor: 4.982

9.  Mechanisms for human genomic rearrangements.

Authors:  Wenli Gu; Feng Zhang; James R Lupski
Journal:  Pathogenetics       Date:  2008-11-03

10.  A novel X-linked gene, G4.5. is responsible for Barth syndrome.

Authors:  S Bione; P D'Adamo; E Maestrini; A K Gedeon; P A Bolhuis; D Toniolo
Journal:  Nat Genet       Date:  1996-04       Impact factor: 38.330

View more
  2 in total

Review 1.  TAZ encodes tafazzin, a transacylase essential for cardiolipin formation and central to the etiology of Barth syndrome.

Authors:  Anders O Garlid; Calvin T Schaffer; Jaewoo Kim; Hirsh Bhatt; Vladimir Guevara-Gonzalez; Peipei Ping
Journal:  Gene       Date:  2019-10-21       Impact factor: 3.688

2.  A novel mutation in TAZ causes mitochondrial respiratory chain disorder without cardiomyopathy.

Authors:  Nurun N Borna; Yoshihito Kishita; Kaori Ishikawa; Kazuto Nakada; Jun-Ichi Hayashi; Yoshimi Tokuzawa; Masakazu Kohda; Hiromi Nyuzuki; Yzumi Yamashita-Sugahara; Takashi Nasu; Atsuhito Takeda; Kei Murayama; Akira Ohtake; Yasushi Okazaki
Journal:  J Hum Genet       Date:  2017-01-26       Impact factor: 3.172

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.